Overview

The study aimed to determine whether IL-17A plays a role in modulating synaptic plasticity in the striatum, particularly in medium spiny neurons (MSNs), which are central to basal ganglia function. While IL-17A has been studied in cortical regions, its role in subcortical structures like the striatum remained unclear. The researchers used genetic mouse models lacking IL-17A or IL-17RA, electrophysiological recordings, and molecular analyses to explore how this cytokine influences synaptic function.

This work is significant because it bridges immunology and neuroscience, offering insights into how immune molecules can influence brain circuits involved in movement and cognition. It also opens new avenues for understanding the role of immune dysregulation in neurological and psychiatric disorders.

Key findings

The study found that IL-17RA is widely expressed in striatal MSNs and interneurons. IL-17A was also detected in microglial cells within the striatum, suggesting a local source of this cytokine. In mice lacking IL-17A or IL-17RA, long-term potentiation (LTP)—a key mechanism of synaptic plasticity—was significantly reduced. This indicates that the IL-17 axis is involved in maintaining normal synaptic function.

Further analysis revealed that the absence of IL-17A led to a reduction in the GluN2B subunit of NMDA receptors at synaptic sites, which are critical for LTP induction. Interestingly, when brain slices were exposed to high levels of IL-17A, LTP was impaired, and NMDA receptor function was altered, particularly through changes in the GluN2A subunit.

The researchers also identified glycogen synthase kinase-3 beta (GSK-3β) as a downstream effector of IL-17RA signaling. Inhibiting GSK-3β partially restored LTP in slices exposed to high IL-17A levels, suggesting that this kinase contributes to IL-17A-induced synaptic changes.

The role of antibodies

To investigate the expression of IL-17A and IL-17RA in the brain, the researchers used immunofluorescence techniques with specific antibodies. Abcam’s Anti-IL-17RA antibody was used to detect IL-17RA expression in neurons and interneurons.

This antibody enabled precise localization of IL-17A and its receptor in brain tissue, supporting the hypothesis that IL-17 signaling directly affects neuronal populations in the striatum.

Implications

The findings suggest that IL-17A is not only involved in immune responses but also plays a role in regulating brain function. Under normal conditions, IL-17A supports synaptic plasticity, but when overproduced, it can impair neuronal communication. This dual role may be relevant in diseases where inflammation is present, such as multiple sclerosis, Parkinson’s disease, and certain psychiatric disorders.

The study also highlights the potential of targeting IL-17A or its downstream pathways, such as GSK-3β, to modulate synaptic function. This could lead to new therapeutic strategies for conditions involving basal ganglia dysfunction.

Future work

Future research will likely focus on understanding how different IL-17 family members influence synaptic function and whether similar mechanisms operate in other brain regions. Studies are also needed to explore how IL-17A affects behavior and cognition, particularly in models of neurodegenerative and psychiatric diseases.

Further investigation into the cell-specific effects of IL-17A in D1- and D2-type MSNs could provide more detailed insights into how this cytokine shapes striatal output. Additionally, exploring the interaction between IL-17A and dopaminergic signaling may help clarify its role in mood regulation and motor control.

References

1. Mancini A, Bellingacci L, Canonichesi J, et al. Immune control of the basal ganglia network: interleukin-17 as a key modulator of striatal synaptic plasticity. Neurobiol Dis. 2025.